Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries... Show more
Mettler-Toledo International Inc. (MTD), a leading supplier of precision instruments for life sciences, industrial, and food sectors, released its fiscal first quarter 2026 results on May 7, 2026. This report is critical amid volatile markets, as investors assess resilience in lab and analytical equipment demand. Following a strong Q4 2025 where sales grew 8% and adjusted EPS hit $13.36, Q1 tests ongoing trends like automation and onshoring. With shares near $1,320, the results signal operational strength but highlight macro headwinds, influencing views on margins and growth in a high-interest-rate environment. For shareholders, execution on innovation and cost controls remains key to sustaining profitability.
Mettler-Toledo delivered Q1 2026 net sales of $947.1 million, surpassing consensus estimates of $943 million by 0.4% and up 7% from $883.7 million in Q1 2025 on a reported basis. In local currency terms, sales rose 3%, or 1% excluding acquisitions—flat in the Americas but up 3% in Asia/Rest of World. Regional reported growth was strongest in Europe (+12%) and Asia/Rest of World (+8%).
GAAP diluted EPS increased 7% to $8.33 from $7.81, while adjusted EPS (non-GAAP, excluding amortization, restructuring, and other items) climbed 9% to $8.91 from $8.19, exceeding expectations of $8.70-$8.75. This beat was driven by solid margin execution, with adjusted operating profit at $246.2 million (26.0% margin), up 4% despite a slight dip from 26.8% last year. Gross margin was 58.7%, down modestly from 59.5% due to mix and costs.
Earnings before taxes reached $209.7 million, up from $201.9 million. CEO Patrick Kaltenbach noted strong execution in an uncertain environment, crediting innovation investments. Guidance updates include Q2 local currency sales growth of ~3% and adjusted EPS of $10.70-$10.85 (below prior consensus ~$10.96); full-year local currency sales ~4% and adjusted EPS $46.30-$46.95 (slight raise from $46.05-$46.70).
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (e.g., large-cap like MTD), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like precision instruments. Explore it today to uncover potential opportunities tailored to your strategy.
Post-release on May 7, MTD shares declined about 0.5%-1.1% in after-hours trading, trading around $1,320 despite the EPS beat. Investors appeared cautious on modest organic growth (1% ex-acquisitions) and Q2 guidance implying adjusted EPS growth of 6%-8% below some consensus views (~$10.96). Sentiment reflects balanced execution amid macro uncertainty, with prior quarters showing beats but mixed reactions tied to guidance. Broader healthcare equipment sector stability supported resilience, though tariff and inflation concerns lingered.
Mettler-Toledo's updated FY 2026 guidance projects ~4% local currency sales growth, unchanged from prior views, with adjusted EPS of $46.30-$46.95 signaling 8%-10% expansion. This reflects confidence in core markets despite headwinds.
Q2 guidance flags ~3% local currency sales growth and adjusted EPS of $10.70-$10.85. Investors should watch regional dynamics: Americas stability, Europe's currency impacts, and Asia's onshoring tailwinds. Government grants ($6.2 million in Q1, more expected) bolster automation investments.
Key monitors include operating margins (targeted +60-70 bps ex-FX annually), free cash flow (~$900 million projected), and share repurchases ($825-$875 million). Restructuring ($7.3 million in Q1) and amortization trends merit attention. Broader factors: tariffs, inflation on costs, and demand for precision tools in life sciences and food safety. Upcoming catalysts: Q2 results and macro updates on trade/geopolitics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
a manufacturer of precision instruments
Industry MedicalSpecialties